

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/511,537	First Named Inventor: Hanson
371 Filing Date: October 15, 2004	Attorney Docket No.: 100647-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 4417
Title: Thioxanthine Derivatives as Myeloperoxidase Inhibitors	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Pursuant to the duty of disclosure in accordance with 37 C.F.R. § 1.56, Applicants submit herewith a list of references on accompanying Form(s) SB08.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement and accompanying Form(s) SB08 shall not be construed as a representation that a search has been made or that the references cited are material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i) only copies of foreign patent documents; Office Actions issued in co-pending U.S. applications; non-patent publications; English language abstract(s) and/or translations of non-English language foreign patent document(s) or non-patent publication(s); and International Search Report(s) (ISR(s)) are submitted herewith.

It is applicants understanding that although Examiners consider ISR(s), they are not typically listed on the front of the issued patent, and are therefore normally crossed off the SB08 form. Accordingly, unless indicated in the record otherwise, it will be assumed the Examiner has considered the ISR(s) cited in the accompanying SB08 form(s).

In addition, Applicant(s) wish to call the Examiner's attention to the following commonly-owned co-pending patent application:

- 1) U.S. Application Serial No. 11/756967, Attorney Docket No. 102288-2 US, filed June 1, 2007.

In accordance with the provisions of 37 C.F.R. 1.97, this statement and accompanying Form(s) SB08 are being filed before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US.

Respectfully submitted,

/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen
Dated: October 30, 2007
Reg. No.: 51,574
Phone No.: 302-885-4269
Global Intellectual Property, Patents,
AstraZeneca
1800 Concord Pike
Wilmington
DE-19850-5437